ARTICLE | Company News
Cytokine other research news
July 27, 1998 7:00 AM UTC
The company received two $100,000 Phase I SBIR grants from the National Cancer Institute, funding studies of the potential for the agent to prevent toxicity from IL-2 and IL-12 in cancer treatment. ...